The first four new types of caffeinated citrate injection approved for marketing is deemed to have passed the consistency evaluation

On February 21, the caffeinated citrate injection declared by China Resources Shuanghe according to the new four categories was approved for listing, which was deemed to have passed the consistency evaluation This is the first manufacturer in China to pass the consistency evaluation of the drug The original manufacturer of caffeinated citrate injection is Casey Pharmaceutical Co., Ltd at present, the drug has become the first choice in clinical treatment of premature infants with apnea in Europe and the United States It has been clearly recorded in the current world health organization core basic drug standard directory and children's basic drug standard directory, and has become one of the commonly used drugs in neonatal intensive care unit (NICU) abroad In addition to the original research manufacturers in the domestic market, there are three enterprises, Sinopharm group, Guorun pharmaceutical and Yuandong biology, which are listed to sell the drug Among them, Guorun pharmaceutical and Yuandong bio have respectively submitted application for conformity assessment In addition, Southwest Pharmaceutical, Hefeng pharmaceutical and Xingxing pharmaceutical are also declared to produce according to the new 3 / 4 categories.